Real-world data on targeted drug for advanced breast cancer in russia

NCT ID NCT07281001

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 26 times

Summary

This study is looking at how well the drug trastuzumab deruxtecan works in Russian patients with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Researchers will review medical records from 60 patients who have already received the drug to see how long they live without the cancer growing and how safe the treatment is. The goal is to understand real-world effectiveness in this specific population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation

    RECRUITING

    Moscow, 115522, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.